Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Conditions

Fatigue 6Brain Neoplasms 3Sleep Wake Disorders 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Pain 1Mental Disorders 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Depression 1Central Nervous System Neoplasms 1Caregiver Burden 1Breast Neoplasms 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × Methylphenidate × Clear all
NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled 7 charts

Fatigue, Neoplasms

NCT00129467 2015-04-24

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

VA Office of Research and Development

Phase NA Completed
47 enrolled 13 charts

Caregiver Burden, Mental Disorders, Depression, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡